论文部分内容阅读
1998年5月30日,中华医学会科技发展中心在北京举行了“基因工程药物在创伤修复(愈合)临床应用中的新进展暨国家一类基因工程新药‘贝复济’正式批准上市报告会”。我国著名创伤学专家、中国工程院院士黎鳌、盛志勇、王正国,中华医学会党组书记兼秘书长刘海林、副会长王镭,以及来自全国各地出席首届全国创伤修复(愈合)与组织再生交流会的200余位代表参加了报告会。 “贝复济”于1990年列入国家“八五”科
On May 30, 1998, the Chinese Medical Science and Technology Development Center held a new progress in the clinical application of genetically engineered drugs in wound repair (healing) in Beijing. The First Class of Genetically-modified New Drugs ’Bei Fuji’ formally approved the listing report “. Li Ao, Sheng Zhiyong and Wang Zhengguo, academician of Chinese Academy of Engineering, Liu Hailin, secretary general of the Chinese Medical Association and Wang Lei, vice president of the Chinese Medical Association, as well as experts and scholars from all over the country attending the first nationwide exchange of trauma rehab (healing) and tissue regeneration More than 200 delegates attended the report. ”Bei Fuji“ was included in the ”Eighth Five-Year Plan" section in 1990